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Digenic inheritance (DI) concerns pathologies with the simplest form of multigenic etiology,
implicating more than 1 gene (and perhaps the environment). True DI is when biallelic or even
triallelic mutations in 2 distinct genes, in cis or in trans, are necessary and sufficient to cause
pathology with a defined diagnosis. In true DI, a heterozygous mutation in each of 2 genes
alone is not associated with a recognizable phenotype. Well-documented diseases with true DI
are so far rare and follow non-Mendelian inheritance. DI is also encountered when by serendip-
ity, pathogenic mutations responsible for 2 distinct disease entities are co-inherited, leading to
a mixed phenotype. Also, we can consider many true monogenic Mendelian conditions, which
show impressively broad spectrum of phenotypes due to pseudo-DI, as a result of co-inheriting
genetic modifiers (GMs). I am herewith reviewing examples of GM and embark on presenting
some recent notable examples of true DI, with wider discussion of the literature. Undeniably,
the advent of high throughput sequencing is bound to unravel more patients suffering with
true DI conditions and elucidate many important GM, thus impacting precision medicine.
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1 | INTRODUCTION
The advent of next generation sequencing (NGS) technologies during
the past decade, inescapably leads to finding variants we would not
have found previously, which may or may not have significance for, or
impact, the phenotype. This realization makes it very important to
apply measures of discriminating the pathogenic from the neutral vari-
ants. Based on several measures of evaluating the pathogenicity of
DNA variants they are classified as clearly or likely to be pathogenic,
of unknown significance, unlikely to be pathogenic or clearly not path-
ogenic.1 It is worth noting that between the concept of a clearly path-
ogenic and a clearly not pathogenic DNA variant there is an abyss of
variants of variable functional significance. Things become more com-
plicated when we implicate not 1 but 2 or more DNA variants to
describe the symptoms and justify the diagnosis; which is where
digenic inheritance (DI) and genetic modifier (GM) come into play.
One particular class of interesting mutations is those described as
hypomorphic. Hypomorphic mutations (one type of Muller’s Morphs,
after Nobel laureate Hermann J. Muller), lead to reduced gene activity
(as opposed to hypermorphic mutations, which lead to increased gene
activity). They refer to clearly mutant DNA variants which retain some
residual activity. Depending on several factors and the specific gene at
fault, 2 or more such mutations are required to be co-inherited in cis
(on same chromosome and genetically linked) or in trans (on different
alleles of same gene or on 2 different genes) in order to produce a rec-
ognizable phenotype and such mutations may account for cases with
incomplete penetrance. They are clearly different from recessive
mutations which can be severe but yet insufficient to confer a pheno-
type because the 1 normal dose from the wild-type allele is sufficient
to maintain homeostasis and health. It is frequent, for example, to
have severe, even non-sense mutations with total loss-of-function,
especially in enzymes, that act as recessive in healthy carriers.
Speaking of clearly pathogenic mutations in monogenic disorders,
1 genetic defect may be responsible for the expression of a disease
phenotype, which describes a defined diagnosis. When concentrating
on the mutated gene, the full spectrum and/or the severity and/or
the age-at-onset of the disease may be determined by several
factors:
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1. The specific mutated gene (consider genetic heterogeneity).
2. The position of the mutation in the protein (ie, specific functional
domain, N-terminal or C-terminal).
3. The nature of the mutation, that being a single nucleotide substi-
tution, a small indel or a large deletion/insertion, a termination
codon, a splice site defect or a frameshift.
4. In cases of single aminoacid substitutions, the actual nature of the
substitution, in terms of the size and the biochemistry of the
involved aminoacid side chains (charged vs not-charged and
hydrophilic vs hydrophobic).2 This also applies to DI as shown
below.
2 | DIGENIC INHERITANCE AND GENETIC
MODIFIERS
I can think of 3 distinct examples of DI:
1. True DI, strictly speaking non-Mendelian, as the simplest form of
oligogenic inheritance. An important element is that the patient
will only manifest the disease when 2 non-allelic mutations, on
separate genes are co-inherited, as necessary and sufficient to
elicit the phenotype. A patient with steroid-resistant focal seg-
mental glomerulosclerosis (FSGS), had inherited 2 heterozygous
mutations, 1 each in the podocin and nephrin genes.3
2. Inheritance of a single primary mutation that establishes the diag-
nosis and a second DNA variant, which modifies the phenotype,
exacerbating the clinical picture, under a pseudo-DI scenario.
One expects a broad phenotypic spectrum depending on the
gene(s) at fault. The putative GM is only causative when co-
inherited on the background of a primary “driver” mutation.
When introducing the concept of GM, we accept there is no limit
to the number of such modifiers that might have a perceptible
contribution to the phenotype. One could envision that a single
major modifier is adequate to discernibly accentuate the clinical
presentation or multiple ones alike, with separate or synergistic
influence. Consider a variant in the 50 end of TGFbeta1 that mod-
ifies lung disease in cystic fibrosis (CF).4
3. Coincidental independent segregation of 2 separate disease enti-
ties, each one caused by mutations in separate linked or unlinked
genes/loci. Each one follows a classic Mendelian mode of inheri-
tance. A rare occurrence is the co-inheritance of polycystic kid-
ney disease and Marfan syndrome.5
Sometimes the borders of the scenarios described may be blurred
owing to the huge and still largely incomprehensible complexity of the
human genome, but I hope the readers agree that true DI should be
crystal-clear as the simplest case of oligogenic inheritance not follow-
ing Mendelism, as defined above. The concept of GM acting as con-
comitant heritable events in pseudo-DI, offers potentially the most
blurred scenario, conditional to their contribution in different disease
entities, which admittedly may not always be easy to decipher, owing
to their nature as quantitative traits of variable effect size.
In true DI, either of the 2 mutations alone does not lead to a per-
ceptible phenotype. This definition deterministically implies no
Mendelism. Perhaps this is where I somewhat differ with the broader
definition that Schaffer gave in his elegant review, where in his DI
definition he included cases that “can be better explained” by invok-
ing the contribution of 2 variants at different loci, linked or unlinked,
than each one on its own.6 Without being dogmatic, such situations
should not be classified as genuine true DI. Rather, they would be
better viewed as monogenic and the variable phenotype attributed to
the role of modifier(s) or genes adding other symptoms, than to the
role of a second gene as necessary and sufficient, in determining
whether or not a disease phenotype will manifest (pseudo-DI). I
believe most experts would agree that a GM is a DNA variant that
exerts an epistatic effect on the phenotype, which is invariably deter-
mined by a primary gene. The variable expressivity (clinical or pheno-
typic heterogeneity), may be confounded by the contribution of one
or more GM. This phenotypic heterogeneity, which sometimes can
be hugely extensive ranging from very benign to very severe and life
threatening, is part of the spectrum of symptoms which pertain to
the genotype/phenotype correlation focusing on the primary gene at
fault.7–9 Therefore, the final phenotype in a Mendelian monogenic
disorder can be an amalgamation of multiple factors: (1) the actual
mutated gene (and the kind and position of the primary decisive
mutation), (2) the co-inheritance of GMs that may predispose to a
more severe or milder phenotype, (3) somatic mosaicism and other
atypical patterns of inheritance,10 including epigenetic phenomena,
and (4) environmental factors which may or may not be known,
although amply suspected.
3 | PRIMARY MUTATIONS AND GENETIC
MODIFIERS AS EXAMPLES OF PSEUDO-DI
It has been proposed that GM influence the end-deep phenotype of
Mendelian disorders, in terms of the full spectrum and/or the severity
and the age-at-onset. It is not an innovation on my part to expect that
this scenario will prove to be the most prevalent, involving many if not
most classical monogenic conditions, characterized by extreme clinical
heterogeneity, reminiscent to a phenotypic chameleon. This pheno-
typic chameleon is evident in inter-familial and even intra-familial het-
erogeneity, reflected in incomplete penetrance or in severe (or mild)
and with early (or late) onset symptoms, depending on the disease.
The hitherto used approach by researchers that witness patients
with same diagnosis and similar pathogenic variants, but placed on a
broad spectrum of symptoms, is the search for contributory DNA var-
iants in candidate modifier genes. These could be the second or third
gene that is responsible for the same monogenic disease, owing to
known genetic heterogeneity. Excellent examples are the long QT
syndrome and Bardet-Biedl syndromes, each caused by mutations in
one of more than a dozen genes, Alport syndrome (AS) with 3 genes
(COL4A3/COL4A4/COL4A5)11; cystinuria (SLC3A1/SLC7A9)12; poly-
cystic kidney disease (PKD1/PKD2)13; inherited cardiomyopathies
with mutations in 8 sarcomere genes accounting for only 60% of
cases14 and numerous others. Equally good candidates are genes
encoding proteins partaking in the same protein complex (trimeric
collagen genes, multimeric receptors), or genes coding for interacting
partners, or for proteins the function of which converges to the same
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pathogenetic pathway or participate in higher structures (eg, glomer-
ular slit diaphragm). Epistatic genes that may affect rates of transcrip-
tion or mRNA stability, in the form of epigenetic interference of
miRNAs, cannot be excluded.
A prime example of the role of GM in monogenic glomerulopa-
thies, is thin basement membrane nephropathy (TBMN) when it is
caused by heterozygous COL4A3 or COL4A4 mutations. These
patients are actually the carriers of the autosomal-recessive form of
AS (ARAS), who are not healthy but instead they present with
autosomal-dominant familial microscopic hematuria (MH). This condi-
tion was formerly known as familial benign hematuria. However, volu-
minous data documented that although many patients will stay for life
with isolated MH, others will exhibit a progressive glomerulonephritis
and FSGS, with proteinuria and kidney function decline, even end-
stage renal disease (ESRD) later in life (average age 56 years).15 We
refer to this condition as later-onset Alport-related nephropathy while
several other authors name it autosomal-dominant AS, in most cases
without extra renal features.16,17 We and others hypothesized that
the co-inheritance of GM might account for the long-term predisposi-
tion of a subset of patients to severe or mild disease.
Our thesis is that on long follow-up, the full phenotypic spectrum
of patients presenting with MH, behaves as a multifactorial condition,
implicating primary genes, modifier genes and environmental factors.
We published on 2 DNA variants in the NPHS2 (podocin) gene (p.
Arg229Gln, p.Glu237Gln), the product of which is part of the slit dia-
phragm of the glomerular filtration barrier, interacting with nephrin
(Figure 1). Mutation NPHS2-p.Arg229Gln was previously linked to
steroid-resistant nephrotic syndrome, a highly heterogeneous
autosomal-recessive nephropathy. In functional cell culture
experiments, the alternative variant proteins impaired the interaction
with other slit diaphragm partners and interfered with normal traf-
ficking, demonstrating perinuclear staining.18 More recently we
reported on the putative predisposing role of a variant in the NEPH3
gene (filtrin), also a component of the podocyte slit diaphragm.19
Patients carrying heterozygous COL4A mutations and co-inheriting
the variant NEPH3-p.Val353Met had an increased risk to progressive
kidney failure. Further work with undifferentiated podocytes showed
disturbance of variant p.353Met homo-dimerization and hetero-
dimerization with nephrin, while p.353Met elicited the activation of
the unfolded protein response pathway when overexpressed in
stressed cultured cells, thus attesting to its functional significance.
Importantly, genetic epidemiology studies combining the general pop-
ulation cohorts of Framingham, KORAF4 and SAPHIR studies
(11 258 individuals), revealed significant association with micro-
albuminuria in homozygous subjects19 (Figure 2).
In another work we reported on the epistatic role of MYH9/
APOL1 region on familial hematuria genes. Exploiting several cohorts
of patients with familial hematuria as a common finding, we showed
association of “Severe” disease in CFHR5 nephropathy (a form of C3
glomerulopathy) with MYH9 variant rs11089788 that we confirmed
in an independent cohort. Previous genome-wide association studies
have identified variants in the MYH9 and its closely linked APOL1
gene to confer major susceptibility towards ESRD in various types of
renal diseases.20
In the same Cypriot CFHR5 nephropathy cohort, we presented
evidence for yet another putative modifier.21 Specifically, a variant in
the target site of miR-1207-5p in the 30 UTR of HBEGF was associ-
ated with severity of disease. HBEGF (heparin binding epidermal
FIGURE 1 In family CY5376, NPHS2 variant p.Arg229Gln segregates with severe phenotype, on the background of collagen-IV nephropathy
and thin basement membrane nephropathy (TBMN) due to inheritance of mutation COL4A3-p.Gly1334Glu (COL4A3:1334G/E). Black symbols:
patients heterozygous for the mutation; (+) symbol: severe phenotype. Patient II-7 also has a severe phenotype, which is attributed to his co-
occurrence of TBMN and vesicoureteral reflux (VUR). Some other patients are heterozygous for the risk variant p.Arg229Gln and have mild
disease but are still very young and consequently cannot be classified as “Mild” or “Severe” (filled grey symbols). The 2 patients marked with an
(×) symbol had exhibited VUR in childhood. WT: normal; COL4A3:1334G/E: heterozygous for COL4A3-p.Gly1334Gln; NPHS2: 229R/Q,
heterozygous for NPHS2-p.Arg229Gln (reproduced with permission from Reference18)
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growth factor) is expressed in podocytes and plays a role in glomeru-
lar physiology.
Notwithstanding the relatively small size of the cohorts we stud-
ied, perhaps our success in identifying candidate GM is attributed to
the reduced genomic complexity of these cohorts. More than 70% of
the TBMN patients carried the same COL4A3 founder mutation, p.
Gly1334Glu, while all CFHR5 nephropathy patients carried the
endemic exon 2 to 3 duplication.
Even though our initial hypothesis provided that GM are variants
which on their own might be purely neutral, we are prepared to accept
that most might represent hypomorphic mutants with residual activity,
which exert an effect when found on the background of a primary
defect. In a looser definition, the serendipitous co-inheritance of the pri-
mary mutation and the modifier can better explain the phenotype. Alter-
natively, they could be recessive mutations, without recognizable
symptoms when inherited singly. One limitation of our investigations is
the relatively small number of subjects with the studied phenotype,
mainly because of the rarity of the hereditary condition and the relative
rarity of the variants (MAF = 2%-3%), thus preventing validation studies
on independent cohorts, which are badly needed. Also, in several similar
occasions the association with GM does not lead to an absolute relation-
ship. This implies that the effect of the modifier no matter how strong it
is, might not be sufficient on its own, therefore more than one may be
necessary or the overall situation is more complex. Also plausible is that
the full spectrum of some monogenic conditions is the result of oligo-
genic rather than strict pseudo-DI, or that the environment has substan-
tial contribution.15,16,22
A few notable examples of GM, accompanied by a variable level
of certainty with regards to their role and actual effect, are discussed
in the following sections.
3.1 | Alport syndrome and focal segmental
glomerulosclerosis
In a consanguineous family segregating X-linked AS a doubly mutant
COL4A5 allele could explain the phenotype in males, which, however,
was of unusually early onset. An infant brother had presented with
nephrotic syndrome and progressed to ESRD by the age of 3 years
and a young sister by 8 years. This unusual severity, supported by
biopsy results of podocyte foot processes fusion, prompted more
studies in podocyte-related genes. Two in cis variants in homozygos-
ity affected highly conserved aminoacids in the MYO1E gene, p.
(Lys118Glu) and p.(Thr876Arg).23 MYO1E encodes a podocyte-
expressed non-muscle myosin and is a rare cause of familial FSGS
and nephrotic syndrome.24 This case is placed on the borderline
between genetic modification and independent segregation of 2 sepa-
rate disease entities, as either one alone generates a phenotype. The
expression of both genes in the glomerulus inescapably renders either
one modifier of the other.
3.2 | Autosomal-dominant polycystic kidney disease
and DKK3
Severity in autosomal-dominant polycystic kidney disease (ADPKD) is
primarily determined by the mutated gene (PKD1 vs PKD2), with the
PKD2 mutations associated with more than a decade later age-at-
onset. Nevertheless, GM has been implicated. Perhaps the strongest
one, which, however, has not been replicated in a second study, is a
variant in the DKK3 gene that antagonizes the Wnt/β-catenin signal-
ing and thus modulating cyst growth.25 A recent publication reported
that the same protein constitutes an immunosuppressive and a profi-
brotic epithelial protein that might even serve as a potential thera-
peutic target and diagnostic marker in renal fibrosis.26
3.3 | Ciliopathies
In the genetically heterogeneous group of ciliopathies, patients in a
nephronophthisis cohort had a 7-fold increased risk for retinal degen-
eration if they carried a DNA variant in the AHI1 gene. AHI1 encodes
a cilium-localized protein and was not the primary gene at fault,
therefore, apparently it conferred a strong modifying effect.27
Another example is a common variant (p.A229T) in the RPGRIP1L
(retinitis pigmentosa GTPase regulator-interacting protein-1 like), a
ciliary gene mutated in Meckel-Gruber (MKS) and Joubert (JBTS) syn-
dromes. This variant conferred a higher risk for retinal degeneration
in patients with hereditary ciliopathies due to mutations in other
genes.28 The unusually large repertoire of genes mutated in ciliopa-
thies serves as an exemplar of recessive genes, encoding proteins co-
localized in macromolecular structures of prime significance (in this
case, the primary cilium of epithelial cells), which are common targets
for variants that act as GM. In fact this is a lesson we are learning as
FIGURE 2 A hypothetical model to explain the severe disease
phenotype of patients with heterozygous COL4A3/COL4A4
mutations who develop later-onset Alport-related nephropathy.
When searching for modifiers amongst genes expressed in the renal
glomerulus, we identified variant NEPH3-p.Val353Met. In addition to
its contribution by increasing the risk to severe disease on statistical
grounds, functional studies corroborate its role. The alternative allele
interferes with its homodimerization and heterodimerization with
nephrin, the most important component of the slit diaphragm, part of
the glomerular filtration barrier. The variant in heterozygosity confers
a risk only when co-inherited on the background of a collagen-IV
nephropathy; however, in homozygosity on its own may increase
susceptibility to albuminuria (reproduced with permission from
Reference19)
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we go ahead; that is, the first likely candidate as GM are peer gene
products.
3.4 | Cystic fibrosis
A classical monogenic disease of autosomal-recessive inheritance is
CF, the most frequent potentially lethal inherited disorder, with a car-
rier frequency of 1/25-30 in most Caucasian populations. Similarly,
CF is recognized to have a polygenic etiology with regards to its full
symptomatology and organ involvement. Many studies that include
candidate gene approach and genome-wide analyses have been per-
formed with variable success. Overall, the variability of symptoms in
CF patients in the various organs is such that even though the allelic
genotype accounts for it to some extent, the contribution of tens of
GM is indisputable. Perhaps the most well-accepted and replicated
one, is a variant in the transforming growth factor beta-1 (TGFβ1),
with a well-known role in airway inflammation and remodeling, thus
affecting asthma and chronic obstructive pulmonary disease.29
With no intention for an exhaustive discussion of GM, we con-
clude this section by observing that their putative action may relate
directly or indirectly to the primary gene’s function, in ways that
might or might not be obvious. Stemming from experience in kidney
disorders, with a hypothesis-driven approach, one can envision the
effect of variants in genes co-expressed in the glomerulus and the slit
diaphragm (for inherited glomerulopathies) or the complement cas-
cade or the cilium for the many complementopathies or ciliopathies,
respectively. However, genes involved in tubulo-interstitial fibrosis,
inflammatory processes, autophagy or the unfolded protein response
signaling cascade may exert a variable effect. Other approaches, using
modern machine learning algorithms and genome-wide searches, shall
enable the non-biased identification of variants with small effect, per-
haps documented only on statistical grounds. Deep phenotyping, the
study of adequately large cohorts and unequivocal functional effect
will empower the chances for success.
4 | BILINEAL INHERITANCE OF 1 DISEASE
OR CO-INHERITANCE OF 2 DIFFERENT
Even for true monogenic disorders, high throughput sequencing
(HTS) has led to the discovery of DI, where in some rare occasions
the patients co-inherit 2 separate genic variants, something that also
can be described as double or trans-heterozygosity. Those genes can
be linked or unlinked. In these cases, obviously, we witness DI (not
true DI) which has nothing to do with non-Mendelian inheritance as
a subset of oligogenic or polygenic inheritance.
4.1 | Bilineal inheritance of autosomal-dominant
polycystic kidney disease
The inheritance of 2 mutations, one each in the PKD1 and PKD2
genes, results in more severe phenotype. Either mutation would
cause classical ADPKD; the DI does not permit evoking non-Mendel-
ism. The best such case of bilineal disease due to trans-heterozygous
inheritance of mutations in both genes was a family reported by Pei
et al.13 Two independently segregating mutations explained the initial
erroneous impression of lack of linkage to either locus. Obviously,
the dual inheritance is compatible with life although the disease
severity in 2 patients was worse than when inheriting each mutation
separately. With regards to genetic counseling and the risk for dis-
ease transmission, each offspring of a doubly affected individual, runs
a 50% risk of inheriting either 1 of the 2 mutations alone, 25% of
inheriting both and 75% of inheriting any combination of mutations.
There is still a 25% likelihood of inheriting none of the mutations.
Interestingly, hypomorphic mutations have been described which
singly cause milder or later onset ADPKD. However, the co-
inheritance of variants in the genes of PKD1, PKD2, PKHD1 and HNF-
1β, exacerbate the phenotype, even leading to unusually earlier age-
at-onset, reminiscent to autosomal-recessive PKD.30 Also, DI was
reported for mutations in the HNF-1α, accompanied by maturity-
onset diabetes of the young-3 (MODY3), where the second mutation
in the HNF-1β in some family members caused urogenital and poly-
cystic thyroid changes.31 In these cases, the co-inheritance of more
than one variant better explained the atypical phenotype.
4.2 | Alport syndrome and related collagen-IV
glomerulopathies
HTS technologies resulted in 2 reports on patients from 15 families
with DI of combinations of mutations in the COL4A3/A4/A5 genes
that confounded the phenotype.11,32 The Alport phenotype and espe-
cially the age-at-onset of ESRD in their 40s, could be better explained
by considering the involvement of 2 mutant loci, which depending on
the nature of the very genes mutated (autosomal or X-linked) results
in complex modes of inheritance with serious implications regarding
risk estimation and consequent prognosis. In particular, the fact that
COL4A3 and COL4A4 are mapped head-to-head on chromosome
2q36-37, makes DI for mutations on alleles in cis, to mimic
autosomal-dominant inheritance with higher risk, 50% for offspring.
4.3 | Simple calculations of likelihood for
coincidental bilineal inheritance
In the absence of solid data regarding the prevalence of true DI, let
us embark on calculations for phenotypes that involve diseases of
more known frequency, in order to create a feeling on the expected
co-inheritance of 2 mutations. How frequently would one expect the
co-inheritance of mutations in unlinked genes each one of which
causes a monogenic phenotype? Simple calculations are as follows:
Inheritance of dominant mutations in 2 genes, when their popu-
lation prevalence is 1/500 (familial hypercholesterolemia; autosomal-
dominant PKD).
The prevalence of couples with 2 affected spouses: 1/500 ×
1/500.
The likelihood for a child inheriting both conditions: 1/500 × 1/
500 × 1/4 = 1/1 000 000.
In the UK, one would expect 6 to 7 affected newborns per year.
In Greece, one would expect 2 to 3 affected newborns every 3 years.
In my country Cyprus, once every about 100 years!
For a frequency of 1/100: 1/100 × 1/100 × 1/4 = 1/40 000.
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The co-inheritance of recessive alleles will essentially match that
for the respective recessive diseases.
Not many dominant disorders have this high frequency. It is
reported that TBMN has an estimated population prevalence of 0.3%
to 1%.33 TBMN is a genetically heterogeneous condition but the
most common form is caused by heterozygous mutations in the
COL4A3 or COL4A4 genes in about 40% to 50% of the cases. So, one
expects patients with double heterozygosity to be even rarer than
1/40 000 live births. This is a simplistic approach for the sake of
deriving a sense of probability to occur, because in reality the situa-
tion is more complex as these 2 genes are linked, mapped next to
each other on chromosome 2q36-37, and therefore, one expects co-
inheritance of 2 mutations occurring either in cis or in trans (see
example further below). Even much rarer is the situation where one
mutation is in the COL4A3 or COL4A4 gene and a second is on the X-
linked COL4A5 gene, defects in which are responsible for the most
common form of classical AS. With an estimated male population
prevalence of 1/5000 (most probably even rarer), the co-inheritance
of 2 mutations by a newborn female comes to: 1/3 125 000 (males
will not inherit the X-linked COL4A5 from the affected father).
Probability of father to have 1 X-linked COL4A5 mutation (X-
linked AS): 1/5000.
Probability of mother to have TBMN due to a COL4A3 or
COL4A4 mutation: 1/313 (simplistically based on an average TBMN
prevalence of 0.65%, where COL4A3/A4 mutations occur in 50% of
TBMN patients).
If the COL4A5 mutation is to be carried by the mother and the
COL4A3/A4 mutation by the father, the probability for either male or
female newborns is the same as above (for estimated frequencies of
relevant genes, see References 33–35).
Several examples of coincidental co-inheritance of different dis-
eases have been reported. The great rarity of such occurrences is
exemplified by the publication of 1 single report where they describe
a young patient who co-inherited ADPKD-type-1 and ARAS. ADPKD
is the most common inherited kidney disorder accounting for the
fourth most common cause of ESRD (prevalence of 1/500-1000).
ARAS affects less than 1/5000 subjects. The patient inherited 3 muta-
tions, 1 in the PKD1 gene and a homozygous mutation from his Turk-
ish consanguineous parents who were first cousins.36 Four additional
papers reported on co-inheritance of ADPKD with other connective
tissue disorders.5,37–39
A recently reported case of coincidental inheritance of recessive
phenotypes pertains to the Perrault syndrome (PS), characterized by
severe hearing loss and primary ovarian insufficiency (POI). In a
Pakistani consanguineous family, 6 patients inherited a known muta-
tion in the CLDN14 gene [p.(Val85Asp)] and developed bilateral sen-
sorineural hearing loss. The proband with PS had co-inherited a
homozygous frameshift SGO2 gene mutation, p.Glu485Lysfs*5, that
was considered responsible for the POI. SGO2 encodes shugoshin
2 and no mutations had been implicated in human disorders before.
In mouse, Sgol2a (encoding shugoshin-like 2a) is necessary during
meiosis in both sexes to maintain the integrity of the cohesin com-
plex that tethers sister chromatids. In support of the pathogenic role
of the SGO2 defect, mutations in other cohesion complex genes also
cause infertility.40 Considering that the proband manifests
2 genetically distinct disorders, deafness and POI, it does not repre-
sent true DI, even though they are the hallmark of the PS.
Based on probabilistic calculations and on documented reported
cases, the occurrence of DI is expected seldom in clinical diagnostic
laboratories; however, if one considers the global population it ought
to happen and should be prepared to recognize it, as it is of scientific
interest and clinical concern. Nevertheless, one expects deviations
from above probabilistic calculations due to varying gene frequencies,
genetic drift and founder phenomena, or genetic isolates in studied
populations. At the same time many patients might remain undiag-
nosed, who have inherited unknown genic combinations resulting in
phenotypes not considered of familial nature, solely due to our
ignorance.
5 | TRUE NON-MENDELIAN DIGENIC
INHERITANCE
5.1 | The DIDA database
The DIDA database is a recent development in genetics databases,
accumulating information on diseases with DI, along with details on
the genes involved, the DNA variants and digenic combinations
detected. It is also a good source for statistics (http://dida.ibsquare.
be/). DIDA has used the definition of true DI when 2 genic mutations
are necessary and sufficient to cause a phenotype and named “Com-
posite” the diseases where there is either independent segregation of
phenotypes or the effect of a driver mutation is modified to a vari-
able extend by secondary variations in gene modifiers. According to
DIDA, among 258 entries 34.88% are true DI, 29.07% are composite
and the rest 36.05% are still not clear. The true DI represent
90 digenic combinations in 54 diseases, with the Bardet-Biedl syn-
drome being the most represented.41 With time, HTS technologies
will uncover novel DI cases but I feel it is still unpredictable how
prevalent they will prove to be. Statistically, it may not be significant
at population level but will have tremendous impact on individual
patient diagnosis and treatment, as applied to personalized medicine.
5.2 | Selected recent publications on true digenic
inheritance
It is not the purpose of this thesis to describe all known diseases that
show true unequivocal DI, as this has been attempted by other excel-
lent reviews. A few elegant examples are worth mentioning and dis-
cussing them against diseases that are discovered to present with DI
but still following Mendelism, except with exacerbation of symptoms.
Perhaps the most easily replicated DI diseases are those caused
by mutations in recessive alleles, which when mutated on their own
also lead to monogenic autosomal-recessive phenotypes. When these
disorders are genetically heterogeneous, one can envision that multi-
ple non-allelic pair-wise combinations of 2 mutations can cause dis-
ease. Prime examples are Bardet-Biedl syndrome, Usher syndrome,
Deafness, retinitis pigmentosa, and others.42 However, in some occa-
sions DI was challenged on the basis that it could be explained by
other mutational events that included only 1 of the 2 genes.43,44 This
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and other similar examples should alert the health professionals
because it influences the mode of action in genetic testing and
counseling of involved parties. A comprehensive list of conditions
reported until 2013 is included in Table 1 of Reference 6. However,
only a minority of those have been replicated independently (see also
Reference 45).
A particularly interesting case of DI is FSHD, a form of muscular
dystrophy with facial and extremity muscle weakness that may pro-
gress to involve both upper and lower extremities. On chromosome
4q35.2 telomere there is DUX4 gene, embedded within a normally
hypermethylated region of D4Z4 repeat units, their number ranging
from 2 to >100 repeats. The methylation status is determined by a
second gene, SMCHD1, on chromosome 18p11.32 (encoding struc-
tural maintenance of chromosomes flexible hinge domain containing-
1). On occasions that the number of D4Z4 repeats are genetically less
than 10, the chromatin is hypomethylated and relaxed, and the DUX4
gene is expressed in skeletal muscle cells, leading to overexpression of
stem cells and germline genes, resulting in apoptotic cell death.
Another prerequisite is that the DUX4 gene is found on a permissive
haplotype that stabilizes its mRNA through the expression of a proper
polyadenylation signal. This leads to a monogenic autosomal-dominant
form of FSHD1. On occasions that the D4Z4 number of repeats is nor-
mal and expected to be epigenetically repressed, mutations in the
SMCHD1 gene, result in hypomethylation and DUX4 gene expression,
again only when the DUX4 gene is embedded in the array of repeats
that allow its polyadenylation and stabilization. This leads to FSHD2. In
a nutshell, expression of FSHD2 requires a genetic background that
allows stable transcripts of DUX4 and mutations in the SMCHD1 which
will result in epigenetic hypomethylation and transcription of DUX4.
The molecular phenotype that segregates with the disease is hypo-
methylation at the D4Z4 locus, on a DUX4 permissive haplotype.46,47
In the field of dilated cardiomyopathy, a new digenic combination
with mutations in the Troponin T Type-2 gene (TNNT2) and in the
Myosin Heavy Polypeptide-7 gene (MYH7) was reported in a consan-
guineous Iranian family. Affected members carried both mutations
whereas the carriers of either mutation were asymptomatic. The
authors used Whole Exome Sequencing (WES) followed by targeted
filtered analysis of the 60 or so genes, normally mutated in this highly
heterogeneous condition.48
A report of DI serving as an exemplar of the vulnerability of
complex protein structures, is CANDLE/PRAAS, a form of
proteasome-associated autoinflammatory syndrome.49 The genes
involved are PSMA3, PSMB4, PSMB8 and PSMB9, in various combi-
nations of loss-of-function double heterozygous mutations. The sin-
gle gene mutation heterozygous parents of the patients were
healthy. The dose of wild-type proteasome complexes might be the
key feature in these macromolecular structures, as only 6.25% of
the final protein structures are expected to be with no mutant sub-
units, in double heterozygosity. This excellent work, supported by
functional experimentation and modeling, exemplifies the usefulness
of WES approaches and highlights that searching for mutations in
partners of proteins that participate in large sensitive structures may
unravel more cases of DI that may either be misinterpreted as
autosomal-recessive inheritance or as incomplete penetrance, when
only 1 mutation is inherited.
Neocleous et al published on 3 Cypriot patients with clinically
diagnosed familial Mediterranean fever (FMF), the most common
hereditary autoinflammatory disease. For yet unclear reasons, it is
not unusual for a variable percentage of patients to be heterozygous
for mutations in the MEFV gene, thus raising the probability of co-
inheriting other contributory mutations under DI.50,51 The authors
screened 128 MEFV heterozygous patients with FMF-like disease. In
addition to the previously found MEFV mutation, 2 patients co-
segregated heterozygous mutations in the NLRP3 gene and another
patient in the TNFRSF1A gene. Both genes are mutated in rare hered-
itary recurrent fever conditions with dominant inheritance; hence it is
worth noting that the heterozygous parents were healthy.52
Several reports on renal genetic studies using NGS have identified
rare patients with 2 mutations in separate genes but it is not clear
whether they act as modifiers to each other or they represent true DI
of nephrotic syndrome.53 In our setup we studied a family where
4 patients have inherited a most likely pathogenic mutation in COL4A5,
p.Asp654Tyr and a putative contributory mutation in the LAMA5 gene,
p.Pro1243Leu. At least 2 previous reports reported on LAMA5 variants
that were associated with FSGS, thus supporting DI in our patients. In
fact, the spectrum of symptoms in 2 males of 57 and 60 years,
included hematuria, proteinuria, FSGS, loss of kidney function and
renal cortical cysts. Mice with a double Lama5 knockout are fatal; how-
ever, mice with a hypomorphic Lama5 mutation (Lama5neo) that
reduces laminin-α5 expression, exhibit proteinuria, hematuria and cys-
tic kidneys.54 It is probable, therefore, that although this might not rep-
resent true DI, the LAMA5-p.Pro1243Leu variant behaves as a
hypomorphic mutation that adds up to the Alport background55
Evidence for true DI was published while this review was in
press, in a Libyan patient with distal renal tubular acidosis (dRTA).
Two heterozygous mutations were identified in the genes ATP6V1B1
and ATP6V0A4, which normally are mutated in autosomal recessive
forms of dRTA.56
Finally, in kidney cyst formation in ADPKD types 1 and 2, the two-
hit hypothesis has been documented in numerous cases.57,58 Specifi-
cally, cyst formation was shown to initiate when inheriting a germinal
mutation and after the occurrence of a second post-zygotic somatic
event that inactivates the other allele of the same gene, PKD1 or PKD2,
which had been inherited from the healthy parent. This understanding
makes ADPKD a recessive condition at the cellular level as 2 loss-of-
function mutations were necessary for clonal cystogenesis.59,60 Addi-
tionally, we and others showed that true DI was sufficient to cause
cystogenesis. Careful examination of the DNA of cyst-lining epithelial
cells, demonstrated trans-heterozygous mutations, where a germinal
mutation had been inherited in the PKD1 (or PKD2) gene and a second
somatic mutation occurred in 1 allele of the PKD2 (or PKD1) gene.61,62
5.3 | Interpretation of pathogenicity of DNA
variants
Although HTS technologies are empowering our approaches, they are
not particularly assisting us in evaluating the pathogenicity of
detected variants. In all truth, they make things more complicated as
we generate many more candidate variants with likely pathogenic or
modifying role that need to be elucidated. One is tempted to
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attribute larger/small driver/modifying roles to novel variants, espe-
cially to non-synonymous SNPs or small indels, a task that even with
today’s technologies is daunting due to limitations on number of
patients and the lack of robust functional assays.
The human genome is extremely polymorphic, while every
human being carries a number of functionally significant mutations,
perhaps in the order of 50 to 100, previously implicated in inherited
disorders,63 which when being true recessive do not confer any rec-
ognizable symptoms. There are serious efforts by several consortia,
depositing information on validated DNA variants that are not
accompanied by perceptible symptoms. Many times the classification
of a variant as clearly non-pathogenic is particularly difficult as there
are no robust functional assays that would allow an unequivocal per-
manent settlement, especially in the absence of meticulous deep phe-
notyping. With regards to approaches taking into consideration the
variant population frequency, let us not forget that several recessive
mutations have relatively high frequencies and global distribution,
causing diseases that include beta-thalassaemia, hemochromatosis,
CF, FMF and others. At the same time, it is reasonable to hypothesize
that there must be many rare “orphan” mutations that have not been
linked yet to known phenotypes/disorders. Many “orphan” mutations
are going to be accounted for when studied by HTS, accompanied by
deep phenotyping. In fact, some very rare genetic disorders may have
not been recognized as heritable yet, only reported as sporadic inci-
dents of unknown heritability.
It has been the experience for many, during the previous years,
when screening for mutations with older laborious methods, to termi-
nate the search when we thought we found 1 mutation (or 2, for
recessive disorders). Therefore, it is inevitable that in numerous occa-
sions a probable co-inherited additional mutation, either in cis or in
trans was missed. If this is true for monogenic disorders imagine the
loss of information we experienced for conditions with digenic or oli-
gogenic inheritance, where other genes of remote function and chro-
mosomal location are involved.
6 | CONCLUDING REMARKS
The complexity of the human genome and its formerly unpredictable
polymorphic nature, inevitably leads to coincidental inheritance of
2 or more variants of functional significance. Many unrelated pheno-
types might present together simply as the result of this probabilistic
occurrence. Importantly, phenotypes primarily caused by a single
driver mutation that largely determines the diagnosis, but exacer-
bated or ameliorated by epistatic effects are expected to be highly
prevalent. Such epistatic effects might represent GM the invocation
of which better explains the phenotype, as a case of pseudo-DI. One
should be prepared to envision not only simple cases where 1 or
2 GM exert a major effect and can explain the pleiotropic phenotype,
reminiscent to a phenotypic chameleon. Perhaps a most likely sce-
nario is to expect multiple variants (tens or hundreds) to exert their
cumulative effects, in ways that are utterly difficult to identify statis-
tically due to weak association when studied singly. Additionally, the
rarity of most monogenic disorders makes it difficult to decipher
through the human genome complexity, unless there are a few modi-
fiers with an unusually strong effect or when following the candidate
variant approach.
Many not-easily recognizable heritable conditions may exist, due
to true DI, masked as non-genetic or sporadic. NGS technologies
enable us to bet that many disorders may be the result of digenism
FIGURE 3 Depiction of our evolving
hypothesis regarding the complex nature of
secondary events that contribute to the
broad phenotypic spectrum (phenotypic
chameleon). This is what we call the genetic
alpha effect. Different patients with a
defined monogenic disease diagnosis, may
inherit additional DNA variants with
variable effect size, amongst many in a
large functional variant pool. Variants with
very large effects (larger shapes) may be
adequate to impact phenotype on their
own. Others with smaller effect (smaller
shapes) may require co-inheritance of
several to become noticeable. Shapes with
same color are envisioned to represent
variants in proteins of common
macromolecular complexes or same/
converging pathways. It is also predicted
that amongst all DNA variants with
contributory role, some may increase
(circles) while others may decrease
(squares) risk to progressive clinical course.
Depending on the overall summation and
potential synergism between protective
and risk factors, the balance may shift and
the patient may end-up with a mild or
severe disease outcome on long follow-up
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involving genes implicated in highly heterogeneous conditions. The
combination of HTS technologies and elaborate bioinformatics tools
is destined to identify hidden disease entities that are caused by DI
or even more complex inheritance. We raise the possibility that in
those occasions of genetic heterogeneity that mutations in several
genes cause the same recessive disorder, a broad repertoire of double
heterozygosities might lead to similar or synthetic phenotypes, not
easily elucidated with older technologies. For example, a recessive
disorder involving 5 genes predicts for 10 pair-wise combinations of
DI and a 6-gene system predicts for 15 pair-wise DI combinations,
thus suggesting that true DI might be more frequent than indicated
by current data. It does not escape our attention that not all pair-wise
mutant combinations will manifest a phenotype.
Finally, we wish to share our proposition for the genetic alpha
effect hypothesis to describe the contributory role of secondary
functional DNA variants, either singly or in concert with others, to
configure the final phenotype (Figure 3). The basic concept is that
on the background of an inherited monogenic condition, the co-
inheritance of one or more such variants from a large pool, which
variably increase or decrease the risk to progression, will determine
whether the patient will end-up with a more severe or milder end-
phenotype. The alpha effect provides for tens or hundreds of vari-
ants with small or medium effect as well as for fewer or even one,
with a larger decisive effect. One fundamental prerequisite of this
hypothesis is that in the human genome there are many functional
variants, unable to cause a recognizable phenotype on their own,
ranging from very rare to very frequent. Most of them remain
obscure or masked and waiting to be discovered. We admit this is a
simplistic schematic representation of the hypothesis and we hope
to refine it as we accumulate more data based on solid experimental
evidence.
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